Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

Clinical trial NCT05244304 · COMPLETED

Trial details

NCT number: NCT05244304
Sponsor: Belite Bio, Inc
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Stargardt Disease 1

Start date: 2022-03-28
Primary completion: 2025-08-04
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.